Burlington Stores and The Leukemia & Lymphoma Society’s (LLS) 15th consecutive year of partnership in the fight against blood cancers was a huge success, to say the least. As LLS’s #1 National Corporate Partner and Honored Friend, Burlington Stores, surpassed their $3.6 million goal by a longshot raising more than a record-breaking $3.8 million!
Funds were raised through a national 12-week in-store promotion, where customers were encouraged to donate to the cause at check-out. The campaign featured young “heroes” who are blood cancer survivors. All donations are used to invest in lifesaving research and breakthrough treatments for blood cancer patients.
This year’s campaign launched in September, Blood Cancer Awareness Month and concluded on November 30. Donations were especially high during the fall and holiday shopping season, when millions of customers could donate to the cause at check out.
Burlington Stores and LLS believe in the power of teamwork, and have proven that each and every donation helps in the fight against blood cancer.
“We’re very grateful for Burlington’s dedicated staff who made this year’s campaign the most successful yet. Burlington is truly bringing us closer to our goal of a world without blood cancers,” said Louis J. DeGennaro, PhD, LLS president and chief executive officer.
Over the past 15 years, Burlington has raised more than $29.4 million to find cures and ensure access to treatments for blood cancer patients around the world. Burlington is proud to be a caring company striving to improve the communities its associates live and work in.
Congratulations to the more than 37,000 Burlington associates in the 593 stores across the United States and in Puerto Rico, and all of their generous customers!
This is the third in a series of blogs covering the 58th ASH Annual Meeting and Exposition (#ASH16).
LLS’s groundbreaking precision medicine clinical trial in acute myeloid leukemia (AML), “has the potential to change the paradigm of AML and other hematologic malignancies,” said Kenneth Anderson, M.D., Dana-Farber Cancer Institute, during a press briefing today at the 58th ASH Annual Meeting and Exhibition in San Diego.
Dr. Anderson, president-elect of ASH (the American Society of Hematology) was the moderator of the press briefing about LLS’s Beat AML Master Trial, launched in October.
The three lead investigators of the trial, Brian Druker, M.D., OHSU Knight Cancer Institute, John Byrd, M.D., The Ohio State University Cancer Center and Ross Levine, M.D., Memorial Sloan Kettering Cancer Center, joined LLS CEO Louis J. DeGennaro, Ph.D., and LLS information specialist Gail Sperling, to discuss the rationale for a new approach to treating AML patients. Later in the day, Dr. Druker presented more details about the trial in a scientific spotlight session on precision medicine.
This is the second of a series of blogs covering the 58th ASH Annual Meeting and Exposition in San Diego (#ASH16) conference over the next few days. Check back for more news from the meeting.
On the first official day of the 58th ASH Annual Meeting and Exposition here in San Diego, scientists from around the world introduced new data from clinical trials for blood cancer therapies. Numerous results offer hope of transforming the way patients are treated and many presentations included LLS-funded research.
LLS is leading the offensive against acute myeloid leukemia (AML), one of the most deadly blood cancers. The linchpin of our initiative, the groundbreaking Beat AML Master Trial, will be in the spotlight tomorrow. But today we saw results from several other LLS-supported projects showing promise for improving outcomes for AML patients as well as reports from other studies of great interest to blood cancer patients.
